Supplementary Tables 1-8 from Targeting TSLP-Induced Tyrosine Kinase Signaling Pathways in CRLF2-Rearranged Ph-like ALL

Supplementary Table S1. Genomic characteristic of ALL PDXs including ALL subtype and key genomic alterations. Supplementary Table S2. Top 5 enriched signaling pathways from the 52 query proteins, as analysed by GO and KEGG pathway analysis platforms. Supplementary Table S3. In vitro combination effects of BMS-754807 and ponatinib. Supplementary Table S4. Differentially expressed genes between Combination and Control (FDR < 0.05). Supplementary Table S5. Differentially expressed genes between BMS-754807 and Control (FDR < 0.05). Supplementary Table S6. Differentially expressed genes between Ponatinib and Control (FDR < 0.05). Supplementary Table S7. KEGG pathway analysis of the differentially expressed genes caused by each treatment condition against control (FDR < 0.25). Supplementary Table S8. Plasma concentration of BMS-754807 and ponatinib as measured by LC-MS/MS.